Anteris Biopharma

Anteris Biopharma is a clinical-stage biotechnology company focused on developing disease-modifying therapies for renal diseases, particularly chronic kidney disease (CKD). A portfolio company of Aditum Bio, the company was formed in 2020 to develop ANT-401 (formerly HPP971), an oral small molecule Bach1 inhibitor in-licensed from vTv Therapeutics. ANT-401 works by inhibiting Bach1 to activate the Nrf2 pathway, which helps regulate antioxidant genes and reduce oxidative stress and inflammation in the kidneys. The company leverages TrialSpark's technology-driven clinical trial platform to accelerate its development programs. In early 2025, the company expanded its leadership team, including the appointment of a Chief Medical Officer, to advance its clinical pipeline.